Upadacitinib for the management of refractory hidradenitis suppurativa, psoriasis, and pyoderma gangrenosum
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
Hidradenitis suppurativa (HS) is a chronic immune-mediated skin disease presenting with recurrent inflammatory nodules, abscesses, draining tunnels, and scarring, most commonly in intertriginous sites. Its estimated global prevalence is approximately 1% and its pathogenesis is complex, involving dysregulation of several pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α and interleukin (IL)-17. HS frequently coexists with systemic inflammatory conditions, such as axial spondyloarthropathies and inflammatory bowel diseases (IBD). Additional associations with dermatologic diseases have been described, particularly with pyoderma gangrenosum (PG). Emerging evidence also suggests a potential link between HS and psoriasis, possibly due to overlapping cytokine pathways. When these conditions occur together, management becomes particularly challenging and may require therapeutic strategies targeting broad inflammatory networks. [...]
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
